Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT® belonging to Curasight's treatment platform No patient safety issues were reported The dosing marks a key milestone with Curasight now in clinical development with both its therapeutic (uTREAT®)...
Hence then, the article about curasight announces successful dosing of first patient in phase 1 trial with utreat in brain cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT® in Brain Cancer )
Also on site :